High cyclin-dependent kinase 5 expression promotes tumor progression in gastric neuroendocrine carcinoma

doi:10.3748/wjg.v32.i26.119574

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 26

This Article

(25)

(18)

(0)

(16)

(1)

(475)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jul 14, 2026; 32(26): 119574
Published online Jul 14, 2026. doi: 10.3748/wjg.v32.i26.119574

Table 1 Patient characteristics of cyclin-dependent kinase 5 high and low groups, mean ± SD/n (%)

Variable	CDK5 high (n = 39)	CDK5 low (n = 26)	P value
Age, years			0.355
≤ 65	21 (53.8)	17 (65.4)
> 65	18 (46.2)	9 (34.6)
Sex			0.908
Female	10 (25.6)	7 (26.9)
Male	29 (74.4)	19 (70.1)
BMI, kg/m²	22.3 ± 2.4	21.8 ± 3.0	0.503
Tumor location			0.279
Upper	23 (59.0)	11 (42.3)
Middle	5 (12.8)	5 (19.2)
Lower	9 (23.1)	10 (38.5)
Mix	2 (5.1)	0 (0)
cT stage			0.002
T2	2 (5.1)	7 (26.9)
T3	10 (25.6)	12 (46.2)
T4	27 (69.3)	7 (26.9)
cN stage			0.032
N0	7 (17.9)	11 (42.3)
N+	32 (82.1)	15 (57.7)
Tumor resection			0.738
Total	27 (69.2)	19 (73.1)
Partial¹	12 (30.8)	7 (26.9)
Tumor length, cm			< 0.001
< 5	8 (20.5)	18 (69.2)
≥ 5	31 (29.5)	8 (30.8)
Number of lymph nodes dissected	31.9 ± 11.9	34.4 ± 11.4	0.398
Metastatic lymph nodes	5.2 ± 5.2	2.8 ± 4.1	0.046
pT stage			0.001
pT1	1 (2.6)	3 (11.5)
pT2	1 (2.6)	9 (34.6)
pT3	15 (38.4)	8 (30.8)
pT4	22 (56.4)	6 (23.1)
pN stage			0.020
pN0	6 (15.4)	9 (34.6)
pN1	7 (17.9)	10 (38.5)
pN2	14 (35.9)	4 (15.4)
pN3	12 (30.8)	3 (11.5)
pTNM stage			< 0.001
I	2 (5.1)	5 (19.2)
II	8 (20.5)	15 (57.7)
III	29 (74.4)	6 (23.1)
Nerve invasion			0.139
Yes	33 (84.6)	18 (69.2)
No	6 (15.4)	8 (30.8)
Vascular invasion
Yes	20 (51.3)	17 (65.4)	0.261
No	19 (48.7)	9 (34.6)
Cell type
Large cell	27 (69.2)	22 (84.6)	0.158
Small cell	12 (30.8)	4 (15.4)

¹Distal or proximal gastrectomy.

BMI: Body mass index; pTNM: Pathological tumor-node-metastasis.

Full Size Table

Citation: Sun YQ, Su J, Ye KN, Chen QX, Kang EZ, Lv CB, Lian MQ, Zeng WM, Zhang YB, Cai LS. High cyclin-dependent kinase 5 expression promotes tumor progression in gastric neuroendocrine carcinoma. World J Gastroenterol 2026; 32(26): 119574
URL: https://www.wjgnet.com/1007-9327/full/v32/i26/119574.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i26.119574

Sun YQ, Su J, Ye KN, Chen QX, Kang EZ, Lv CB, Lian MQ, Zeng WM, Zhang YB, Cai LS. High cyclin-dependent kinase 5 expression promotes tumor progression in gastric neuroendocrine carcinoma. World J Gastroenterol 2026; 32(26): 119574 [DOI: 10.3748/wjg.v32.i26.119574]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.